OptimizeRx Co. (NASDAQ:OPRX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $9.06.

A number of analysts have weighed in on OPRX shares. B. Riley reduced their price target on OptimizeRx from $17.00 to $13.00 and set a "buy" rating for the company in a research report on Tuesday, December 24th. William Blair reiterated an "outperform" rating on shares of OptimizeRx in a report on Thursday, November 14th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $6.00 price target (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Stephens initiated coverage on OptimizeRx in a report on Friday, December 20th. They issued an "equal weight" rating and a $5.50 target price on the stock. Finally, Roth Mkm reiterated a "buy" rating and set a $16.00 price target (down from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th.

Insider Activity at OptimizeRx

In other news, CEO William J. Febbo acquired 20,000 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the purchase, the chief executive officer now owns 601,253 shares of the company's stock, valued at $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of OPRX. Barclays PLC boosted its stake in OptimizeRx by 358.5% in the third quarter. Barclays PLC now owns 26,934 shares of the company's stock worth $208,000 after purchasing an additional 21,060 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in OptimizeRx during the 3rd quarter worth about $810,000. Rice Hall James & Associates LLC grew its holdings in OptimizeRx by 24.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company's stock worth $4,751,000 after acquiring an additional 119,306 shares during the last quarter. BNP Paribas Financial Markets increased its position in OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock valued at $28,000 after acquiring an additional 2,414 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of OptimizeRx by 101.8% in the second quarter. Renaissance Technologies LLC now owns 142,146 shares of the company's stock worth $1,421,000 after acquiring an additional 71,700 shares during the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Stock Up 2.4 %

OPRX stock traded up $0.13 during trading hours on Tuesday, hitting $5.48. The company's stock had a trading volume of 90,001 shares, compared to its average volume of 176,965. The stock has a 50 day moving average price of $5.10 and a two-hundred day moving average price of $6.79. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $16.65. The company has a market capitalization of $100.94 million, a PE ratio of -4.12 and a beta of 1.36. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.